Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    S1108, A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237
Show Display Options
Rank Status Study
1 Active, not recruiting Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma
Interventions: Drug: Alisertib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years